𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Induction of 6-thioguanine-resistant mutants in human diploid fibroblasts in vitro with ethylene oxide

✍ Scribed by Ada Kolman; Tatiana Bohušová; B. Lambert; J. W. I. M. Simons

Publisher
John Wiley and Sons
Year
1992
Tongue
English
Weight
372 KB
Volume
19
Category
Article
ISSN
0893-6692

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Induction of DNA strand breaks by ethyle
Induction of DNA strand breaks by ethylene oxide in human diploid fibroblasts
✍ Jonas Nygren; Björn Cedervall; Stefan Eriksson; Mária Duškinská; Ada Kolman 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 English ⚖ 613 KB

In vitro exposure of normal human diploid fibroblasts (strain VH-10) to ethylene oxide (EtO) induced DNA strand breaks in the dose range of 2.5-30 mMh of EtO. Alkaline DNA unwinding (ADU), neutral filter elution (NFE), pulsed field gel electrophoresis (PFGE), and the comet assay were used to measure

Metabolic cooperation in the selection o
Metabolic cooperation in the selection of thioguanine-resistant mutants does not occur with the human B-lymphoblastoid cell TK6
✍ R. M. Gundel; J. P. O'Neill 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 36 KB

Selection for thioguanine resistant mutants in the eration is not an issue in these cells and show that human B-lymphoblastoid cell TK6 yields the same round bottom wells can be used in place of flat results in both round and flat bottom 96-well microti-bottom wells. Environ. Mol. Mutagen. 30:359ter

The P140K mutant of human O6-methylguani
The P140K mutant of human O6-methylguanine-DNA-methyltransferase (MGMT) confers resistance in vitro and in vivo to temozolomide in combination with the novel MGMT inactivator O6-(4-bromothenyl)guanine
✍ Lorna B. Woolford; Thomas D. Southgate; Geoffrey P. Margison; Michael D. Milsom; 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 155 KB

The O 6 -methylguanine-DNA-methyltransferase (MGMT) inactivator O 6benzylguanine (O 6 -beG) is currently under clinical investigation as a potential tumour-sensitising agent. In clinical trials its use has been associated with increased myelotoxicity and a reduced maximum tolerated dose (MTD) for BC